Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses

Molecular Genetics and Metabolism

Volumn 97, Issue 3, 2009, Pages 234-236

  Burton, Barbara K ^a,b   Wiesman, Chani ^a   Paras, Andrea ^a,b   Kim, Katherine ^a,b   Katz, Rachel ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Enzyme replacement therapy; Home infusion; Hunter syndrome; Mucopolysaccharidoses

Indexed keywords

ANTIHISTAMINIC AGENT; DIPHENHYDRAMINE; GALSULFASE; IDURONATE 2 SULFATASE; STEROID;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; HOT FLUSH; HUMAN; HUNTER SYNDROME; HYPERTENSION; INFUSION; INFUSION RELATED REACTION; IRRITABILITY; MALE; MAROTEAUX LAMY SYNDROME; MOOD DISORDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HOME INFUSION THERAPY; HUMANS; MALE; MUCOPOLYSACCHARIDOSES; PATIENT COMPLIANCE; SAFETY;

EID: 67349153417     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.04.007     Document Type: Article

References (7)

1. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., Okazaki S., Huff K., Cox G.F., Swiedler S.J., and Kakkis E.D. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol. Genet. Metab. 90 (2007) 171-180
2. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswani U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., and Kemura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8 (2006) 465-473
3. Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.I., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Piecko B., Steiner R., Whitley C.B., Kaplan P., Yu Y.F., Swiedler S.J., and Decker C. MPS VI Study Group. Long term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI. Final results of three clinical studies of recombinant human N-acetylgalactosamine-4-sulfatase. Mol. Genet. Metab. 94 (2008) 469-475
4. Cox-Brinkman J., Timmermans R.G.M., Wijburg F.A., Donker W.E., van de Ploeg A.T., Aerts J.M.F.G., and Hollak C.E.M. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible, safe. J. Inherit. Metab. Dis. 30 (2007) 984
5. Bagewadi S., Roberts J., Mercer J., Jones S., Stephenson J., and Wraith J.E. Home treatment with Elaprase, Naglazyme is safe in patients with mucopolysaccharidosis types II, VI, respectively. J. Inherit. Metab. Dis. 31 (2008) 733-737
6. Laney D.J., White A.L., Rhead W.J., and Fernhoff P. Creating genetics-based infusion centers: a case study of two models. Genet. Med. 10 (2008) 626-632
7. Kim K.H., Decker C., and Burton B.K. Successful management of difficult infusion-related reactions in a young patient with mucopolysaccharidosis VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatrics 121 (2008) e714-e717